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Abstract
Introduction: Previous studies and a meta-analysis in surgical patients indicate that supplementing parenteral
nutrition regimens with n-3 polyunsaturated fatty acids (PUFAs), in particular eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), is associated with improved laboratory and clinical outcomes in the setting of hyper-
inflammatory conditions. Refined or synthetic fish oils are commonly used as a source of EPA and DHA. The
objective of the present meta-analysis was to evaluate n-3 PUFA-enriched parenteral nutrition regimens in elective
surgical and intensive care unit (ICU) patients.
Methods: Medline was searched for randomized controlled trials comparing n-3 PUFA-enriched lipid emulsions
with standard non-enriched lipid emulsions (i.e. soybean oil, MCT/LCT or olive/soybean oil emulsions) in surgical
and ICU patients receiving parenteral nutrition. Extracted data were pooled by means of both random and fixed
effects models, and subgroup analyses were carried forward to compare findings in ICU versus non-ICU patients.
Results: A total of 23 studies (n = 1502 patients: n = 762 admitted to the ICU) were included. No statistically
significant difference in mortality rate was found between patients receiving n-3 PUFA-enriched lipid emulsions
and those receiving standard lipid emulsions (RR= 0.89; 0.59, 1.33), possibly reflecting a relatively low underlying
mortality risk. However, n-3 PUFA-enriched emulsions are associated with a statistically and clinically significant
reduction in the infection rate (RR =0.61; 0.45, 0.84) and the lengths of stay, both in the ICU (-1.92; -3.27, -0.58) and
in hospital overall (-3.29; -5.13, -1.45). Other beneficial effects included reduced markers of inflammation, improved
lung gas exchange, liver function, antioxidant status and fatty acid composition of plasma phospholipids, and a
trend towards less impairment of kidney function.
Conclusions: These results confirm and extend previous findings, indicating that n-3 PUFAs-enriched parenteral
nutrition regimens are safe and effective in reducing the infection rate and hospital/ICU stay in surgical and ICU
patients.
Introduction
The role of polyunsaturated fatty acids (PUFA) in the
modulation of biologic activities was identified some dec-
ades ago, starting from the first studies on the lower cardi-
ovascular risk found in populations with an extremely
high intake of n-3 PUFA such as eicosapentaenoic acid
(EPA), and docosahexaenoic acid (DHA) [1,2]. In addition
to being structural constituents of cell membranes, PUFA
are precursors of biological mediators involved in the
regulation of many physiological functions, including
immune response, blood pressure regulation, cell prolif-
eration, blood clotting, and inflammation [3,4]. The
balance between n-3 and n-6 PUFA is important, as med-
iators derived from the n-6 PUFA (mainly arachidonic
acid, AA) favour an inflammatory response, while media-
tors stemming from n-3 PUFA such as EPA and DHA
exert less pro-inflammatory actions.
Intravenous lipid emulsions have been established for
many years as an integral part of parenteral nutrition due
to their high energy density and low osmolarity. These
emulsions are traditionally based on vegetable oils that
are rich in n-6 fatty acids, such as soybean oil. In recent
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years, many trials have explored whether parenteral
nutrition regimens supplemented with n-3 PUFA may be
beneficial in those clinical conditions that are character-
ized by an inflammatory over-response, for example, sep-
sis or pancreatitis, and after major abdominal surgery.
Refined or synthetic fish oils are commonly used as a
source of EPA and DHA and have been incorporated
into a new generation of mixed lipid emulsions.
Chen et al. published a meta-analysis of trials con-
ducted in patients undergoing major abdominal surgery
and found evidence that parenteral n-3-enriched lipid
emulsions in the setting of total parenteral nutrition are
beneficial in terms of relevant clinical outcomes, such as
infection rate and hospital length of stay (LOS) [5]. How-
ever, several studies evaluating the effects of fish oil-
based emulsions in clinical conditions in which such
hyper-inflammation is a characteristic were omitted from
this meta-analysis. Moreover, additional clinical studies
have been published in the interim.
The objective of our study was to provide an updated
and more extensive analysis of the available evidence on
the clinical efficacy and safety of n-3 PUFA-enriched
parenteral lipid emulsions in elective surgical and ICU
patients, as compared to standard (non-enriched) lipid
emulsions, namely, soybean oil, medium-chain triglycer-
ides (MCT)/long-chain triglycerides (LCT) or olive/
soybean oil emulsions.
Materials and methods
The Pubmed database was searched for relevant
papers with the following search string: (“Fatty Acids,
Omega-3"[Mesh] OR “Fish oil”) AND “Parenteral
Nutrition"[Mesh] AND ("Surgical Procedures, Operati-
ve"[Mesh] OR “Sepsis"[Mesh] OR “Systemic Inflamma-
tory Response Syndrome"[Mesh] OR “Intensive Care
Units"[Mesh]). Identified papers were checked for
coherence with the defined inclusion criteria, and the
reference list of those deemed relevant was manually
searched for further relevant studies.
To be included in the present analysis, the retrieved
papers were required to report on the results of rando-
mized clinical trials (RCTs) comparing n-3 PUFA-
enriched lipid emulsions with standard non-enriched
lipid emulsions (that is, soybean oil, MCT/LCT or olive/
soybean oil emulsions) in adult ICU patients and/or in
elective surgery patients, in terms of clinical outcomes,
markers of inflammation and antioxidant status, fatty
acid composition of plasma phospholipids, and/or rou-
tine laboratory parameters (Table 1).
Identified papers were checked to identify whether
results of a single study were published more than once, in
order to avoid double imputation. In such instances, the
secondary publications were considered only for para-
meters that were not reported by the main publication.
Results were analysed both overall, and by subgroup (non-
ICU patients versus ICU patients). Allocation to the ICU
subgroup was driven by the explicit mentioning in the
published paper of an ICU stay, either in the Methods or
in the Results section.
Data were extracted from the text, tables and figures of
the original published papers, without any effort to
retrieve further data by contacting the authors. Mean and
SD were used for the meta-analysis: where these were
not reported, they were calculated by fitting an appropri-
ate distribution to the available data. In case of a missing
SD only, this value was imputed based on the average
SD/mean ratio of included studies reporting on the same
parameter. In the case of more than half of the studies
not reporting the SD, analysis was not conducted on that
parameter. Data pooling was performed with the use of
classical meta-analytic methodology, using the RevMan
5.1 software developed for the Cochrane Collaboration.
The primary analysis was conducted with random effects
models, with Mantel-Haenszel weighting for binary out-
comes, and inverse variance weighting for continuous
parameters. Exploratory analyses based on fixed effects
models were also conducted.
Results
The original search (August 2011) in PubMed yielded 52
hits. Of these, thirty-seven publications were excluded,
as they were not consistent with the inclusion criteria:
thirteen were not clinical trials (eleven reviews, one case
report, one drug development study), three did not
report on any of the analysed outcomes, eight were not
randomized, in two the supplementation was adminis-
tered enterally or orally, in four the study population
was not consistent with the specified criteria, and finally,
seven studies were not conducted in human subjects.
The manual search of the reference lists of the remain-
ing fifteen studies yielded a further eight relevant studies
(Additional file 1).
Thus, a total of 23 studies, including a total of 1,502
patients, were included in the meta-analysis: 13 [6-18]
of these were conducted in patients admitted to the ICU
(n = 762), and 10 [19-28] in patients undergoing major
abdominal surgery and not admitted to ICU (n = 740)
(Table 2).
Checking for duplicate publication of the same data
revealed that the studies by Antebi et al. [6] and Grimm
et al. [20] were subgroup analyses of the same study
fully published by Mertes et al. [27]. We therefore
excluded from the analyses the values reported Antebi
et al. [6] for aspartate aminotransferase (AST), alanine
aminotransferase (ALT) and triglyceride levels, and the
data on hospital LOS recorded in Grimm et al. [20], as
all of these parameters were already in the Mertes et al.
publication [27]. Hospital LOS data were reported as
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median and interquartile range by more than one study:
the corresponding mean and SD values were estimated
after fitting a Weibull distribution to reported data.
Clinical Outcomes
The results of the pooled analyses with the random effects
models (Table 3) indicate no statistically significant differ-
ence in mortality rate between patients receiving n-3
PUFA-enriched lipid emulsions and those receiving the
standard lipid emulsions, soybean oil, MCT/LCT or olive/
soybean oil emulsions. The time point at which mortality
was assessed varied: while 28/30 days mortality was the
most commonly used definition [7,9,16,18], in-hospital
mortality was analysed in one report [19], and in the
remaining studies [14,17,26,27] the endpoint for this out-
come was not specified. This lack of clarity/homogeneity
may somewhat hamper the interpretation of presented
results.
However, n-3 PUFA-enriched regimens are associated
with a statistically and clinically significant reduction in
the infection rate (Figure 1) and LOS, both in the ICU
(Figure 2) and in hospital overall (Figure 3). If only ICU
patients’ data are considered, the reduction in infection
rate is not statistically significant.
Lung gas exchange (oxygenation index), measured in
only two studies in septic ICU patients [7,16], was signifi-
cantly increased in patients receiving 3 PUFA-enriched
parenteral nutrition regimens. No statistically significant
differences between treatments could be detected for
bleeding-related outcomes, including blood transfusion
requirements.
Markers of inflammation, antioxidant status and fatty
acid composition of plasma phospholipids
Use of n-3 PUFA-enriched emulsions significantly increases
the serum concentration of alpha-tocopherol and the per-
centage content of EPA (Figure 4) and DHA (Figure 5) in
phospholipids. However, the content of AA in phospholi-
pids was unchanged by n-3 PUFA enrichment.
There was a significantly greater reduction in IL-6 and
a shift in the generation of leukotrienes towards the leu-
kotriene-5 series, as indicated by the significant absolute
Table 1 Considered outcomes and definitions
Outcome Definition
Mortality Number of deaths as reported/patients receiving at least one treatment
Infection rate Number of nosocomial infections/patients receiving at least one treatment dose
Hospital length of stay (LOS)a Mean (SD) number of hospital days from hospitalization (or intervention) to discharge
ICU LOSa Mean (SD) number of ICU days
Transfused blood units Standard units
Oxygenation index Mean (SD) ratio of partial oxygen pressure (PO2): inspired oxygen fraction (FiO2)
Serum parameters
Alpha-tocopherol Mean (SD) serum concentration, µmol/L
Aspartate aminotransferase (AST) Mean (SD) serum concentration, IU/L
Alanine aminotransferase (ALT) Mean (SD) serum concentration, IU/L
Bilirubin Mean (SD) serum concentration, mg/dL
C-reactive protein (CRP) Mean (SD) serum concentration, mg/dL
Creatinine Mean (SD) serum concentration, mg/dL
Interleukin (IL)-6 change Mean (SD) difference in serum IL-6 levels between end and beginning of infusion, pg/mL
Lactate Mean (SD) serum concentration, mmol/L
Triglycerides Mean (SD) serum concentration, mg/dL
Urea Mean serum concentration, mmol/L
Other laboratory parameters
Leukotriene B5 (LTB5) Ex-vivo production by leukocytesb,
Leukotriene B4 (LTB4)
LTB5/LTB4 ratio Ex-vivo production by leukocytes
Eicosapentaenoic acid (EPA) Content in plasma phospholipids, (% of total concentration)
Docosahexaenoic acid (DHA)
Arachidonic acid (AA)
Prothrombin time, PT (Quick) Laboratory standard
Partial thromboplastin time (PTT) Laboratory standard
Platelets Count, × 103/µL
aWhen reported as median and interquartile range, data were transformed into mean (SD) by fitting a Weibull distribution. bAnalysed in terms of standardised
difference as expressed in heterogeneous measurement units.
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Table 2 Studies evaluating n-3 PUFA-enriched lipid emulsions for parenteral nutrition and reported outcomes/
measured parameters






Clinical outcomes Laboratory outcomes
ICU patientsa (n = 762)
Antebi 2004 [6] Major surgery (20) SO/MCT/OO/FOb SO ASTc, ALTc, CRP, alpha-T,TGc
Barbosa 2010 [7] Sepsis (23) SO/MCT/n-3 TGsd SO/OO H LOS, ICU LOS,
Mortality
CRP, EPA, DHA, AA, LTB4, AST,
ALT, Bilirubin, OI, IL-6, PTT, Lac
Berger 2008 [8] Abdominal aortic
aneurysm (24)
SO/MCT/n-3 TGsd SO/OO Mortality, H LOS, ICU
LOS
EPA, DHA, AA, alpha-T, CRP, TG
Friesecke 2008 [9] Critical medical (165) SO + FOe SO/OO Mortality, Infection rate,
ICU LOS, Bleeding events
IL-6f TBU
Heller 2004 [10] Elective colorectal (44) SO + FOe SO ICU LOS AST, ALT, CRP, Bilirubin, PT
(Quick), PTT, TBU






SO/MCT/OO/FOb SO/OO AST, ALT, TG
Roulet 1997 [13] Elective oesophagectomy
(19)
SO + FOe SO EPA, DHA, AA, BT
Sabater 2011 [14] Acute respiratory distress
syndrome (44)
SO/MCT/n-3 TGsd SO Mortality LTB4
Wachtler 1997 [15] Elective abdominal
surgery (40)
SO/MCT/n-3 TGsd SO/OO Infection rate, H LOS,
ICU LOS
LTB4, LTB5, LTB ratio, IL-6f
Wang 2008 [16] Severe acute pancreatitis
(40)
SO + FOe SO Mortality, Infection rate,
H LOS, ICU LOS
EPA, CRP, OI
Weiss 2002 [17] Gastrointestinal surgery
(23)
SO + FOe SO Mortality, Infection rate,
H LOS, ICU LOS
IL-6g
Wichmann 2007 [18] Major intestinal surgery
(256)
SO/MCT/n-3 TGsd SO Mortality, Infection rate,
H LOS, ICU LOS
AST, Bilirubin, TG, CRP, LTB5, LTB
ratio, alpha-T, EPA, PT (Quick), Cr
Elective surgery, non-ICU patients (n = 740)
Badia-Tahull 2010 [19] Major gastrointestinal
surgery (27)
SO + FOe SO/OO) Mortality, H LOS,
Infection rate
ALT, CRP, TBU, Cr, PlU
Grimm 2006 [20] Radical colorectal cancer
resection (33)
SO/MCT/OO/FO b SO H LOSc alpha-T, AA, EPA, DHA, LTB4,
LTB5, LTB ratio
Jiang 2010 [21] Gastrointestinal
malignancy (203)
SO + FOe SO H LOS, Infection rate,
Bleeding events
IL-6, CrCl
Klek 2005[22] Major abdominal surgery
(58)
SO + FOe SO/OO H LOS, Infection rate ALT, AST, Cr, PlU
Koeller 2003 [23] Major abdominal surgery
(30)
SO/MCT/n-3 TGsd SO LTB4, LTB5, LTB ratio
Liang 2008 [24] Colorectal cancer (41) SO + FOe SO Mortality, Infection rate,
H LOS
IL-6
Linseisen 2000 [25] Major abdominal surgery
(33)
SO/MCT/n-3 TGscd SO alpha-T, AA, EPA, DHA
Makay 2011 [26] Major gastric surgery (26) SO + FOe SO Mortality, Infection rate,
H LOS
AST, ALT, Cr, PlU; Lac
Mertes 2006 [27] Abdominal surgery (249) SO/MCT/OO/FOb SO Mortality, H LOS AST, ALT, TG, Bilirubin
Senkal 2007 [28] Major abdominal cancer
(40)
SO/MCT/n-3 TGsd SO/OO Infection rate AA, EPA, DHA
aAllocation to the ICU subgroup was driven by explicit mention in the published paper of an ICU stay, in the Methods or Results sections of the original article.
bSMOFlipid 20% (Fresenius Kabi): 1000 ml of emulsion contains: soya-bean oil, refined 60.0 g, triglycerides, medium-chain, 60.0 g, olive oil, refined 50.0 g, FO, rich
in n-3-acids 30.0 g. cNot used for meta-analysis as data are from a subgroup of Mertes et al.[27]. dLipoplus 20% (B.Braun): 1000 ml of emulsion contains: medium-
chain triglycerides: 100.0 g, soybean oil, refined: 80.0 g, N-3-acid triglycerides: 20.0 g. eOmegaven 10% fish oil emulsion (Fresenius Kabi): 100 ml emulsion
contains highly refined fish oil 10.0 g containing eicosapentaenoic acid (EPA) 1.25 to 2.82 g, docosahexaenoic acid (DHA) 1.44 to 3.09 g, dl-a-tocopherol (as
antioxidant) 0.015 to 0.0296 g. fData reported by graph only or qualitatively. gNo SD reported. AA, (%) content of arachidonic acid in serum/cellular membranes;
alpha-T, alpha-tocopherol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BT, bleeding time; Cr, serum creatinine; CrCl, creatinine clearance; CRP,
C-reactive protein; DHA,(%) docosahexaenoic acid content in serum/cellular membranes; EPA, (%) eicosapentaenoic acid content in serum/cellular membranes;
FO, fish oil emulsion; Lac, lactate; (H) LOS, (Hospital) length of stay; ICU, intensive care unit; LTB, leukotriene B; LTB ratio, LTB5: LTB4; (n-3) TGs, (n-3) triglycerides;
MCT, medium chain triglycerides; OI, oxygenation index; OO, olive oil emulsion; PlU, serum urea; PT, prothrombin time; PTT, partial thromboplastin time; SO,
soybean oil emulsion; TBU, transfused blood units.
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Table 3 n-3 PUFA-enriched versus standard parenteral lipid emulsions for parenteral nutrition: random effects meta-
analysis
Outcome Studies Patients (n) Effect estimate
Mortality, overall RR 10 847 0.89 (0.59, 1.33)
ICU patients 7 547 0.94 (0.61, 1.45)
Non-ICU patients 3 300 0.58 (0.18, 1.84)
Infection rate, overall RR 11 919 0.61 (0.45, 0.84)*
ICU patients 5 524 0.71 (0.45, 1.12)
Non-ICU patients 6 395 0.53 (0.34, 0.82)*
Hospital LOS, overall MD 15 1169 -3.29 (-5.13, -1.45)*
ICU patients 8 615 -5.17 (-8.35, -1.99)*
Non-ICU patients 7 554 -1.86 (-3.13, -0.59)*
ICU LOS, MD 8 615 -1.92 (-3.27, -0.58)*
CRP, overall MD 7 432 -11.28 (-24.71, 2.16)
ICU patients 6 405 -9.76 (-23.57, 4.04)
Non-ICU patients 1 27 -46.00 (-108.12, 16.12)
IL-6 change, MD 3 105 37.70 (20.23, 55.16)*
Oxygenation index, MD 2 61 50.04 (10.99, 89.09)*
Serum lactate, MD 2 47 -0.29 (-1.38, 0.80)
LTB5, overall SMD 5 183 2.86 (1.22, 4.50)*
ICU patients 3 120 3.35 (0.54, 6.16)*
Non-ICU patients 2 63 2.14 (0.42, 3.85)*
LTB4, overall SMD 6 188 -0.47 (-1.18, 0.23)
ICU patients 4 125 -0.85 (-1.42, -0.27)*
Non-ICU patients 2 63 0.34 (-1.25, 1.92)
LTB ratio, overall MD 4 163 0.07 (0.05, 0.09)*
ICU patients 2 100 0.11 (0.01, 0.22)*
Non-ICU patients 2 63 0.06 (0.05, 0.07)*
EPA, overall SMD 9 271 4.12 (2.99, 5.25)*
ICU patients 6 165 4.65 (2.70, 6.60)*
Non-ICU patients 3 106 3.64 (2.65, 4.64)*
DHA, overall SMD 7 171 1.84 (0.65, 3.03)*
ICU patients 4 65 2.82 (0.17, 5.46)*
Non-ICU patients 3 106 1.33 (-0.11, 2.78)
Arachidonic acid, overall SMD 6 171 0.22 (-0.20, 0.64)
ICU patients 3 65 0.35 (-0.14, 0.84)
Non-ICU patients 3 106 0.14 (-0.62, 0.900
Alpha-tocopherol, overall MD 5 170 12.33 (8.73, 15.93)*
ICU patients 3 104 10.08 (5.39, 14.76)*
Non-ICU patients 2 66 15.25 (14.15, 16.35)*
Prothromin time (Quick), MD 2 300 0.43 (-2.62, 3.47)
Partial thromboplastin time, MD 2 65 10.71 (-30.08, 51.51)
Transfused blood units, SMD 2 209 -0.05 (-0.32, 0.22)
Platelet count 4 160 -6.32 (-31.40, 18.77)
Triglyceride level, overall MD 5 567 10.40 (-13.53, 34.34)
ICU patients 4 368 14.16 (-13.12, 41.44)
Non-ICU patients 1 199 -0.89 (-23.26, 21.48)
Serum creatinine, SMD 3 309 -3.01 (-7.11, 1.08)
Serum urea, SMD 2 53 -0.11 (-0.30, 0.08)
AST, overall MD 7 656 -10.05 (-18.81, -1.29)*
ICU patients 4 373 -10.11 (-27.31, 7.10)
Non-ICU patients 3 283 -8.37 (-17.36, 0.61)*
ALT, overall MD 7 482 -9.85 (-17.49, -2.21)*
ICU patients 3 109 -18.18 (-21.68, -14.68)*
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increase in leukotriene B5 (LTB5), the absolute decrease
of LTB4, and the significantly ameliorated LTB5: LBT4
ratio (Figure 6).
Routine laboratory parameters
The analysis indicates a significant reduction in serum
ALT and AST, with n-3 PUFA-enriched emulsions in
comparison to standard lipid emulsions. However, no sig-
nificant differences between the interventions were
detected in coagulation times, platelet count, serum levels
of triglycerides, C-reactive protein (CRP), or bilirubin.
Fixed effect models
In addition to the differences detected by the random
effects models, fixed effect models also indicate a signifi-
cant effect of n-3 PUFA-enrichment regimens on AST
levels in ICU patients; bilirubin, CRP, and triglycerides in
the overall and ICU populations; docosahexaenoic acid
(DHA) in non-ICU patients, and LTB4 in the overall
population (data not shown).
Discussion
A total of 23 studies (n = 1,502 patients; n = 762 admitted
to the ICU) were included in our meta-analysis. Pooled
data indicate important and significant positive effects of
n-3 PUFA-enriched parenteral regimens over a wide range
of outcomes in the selected patient populations. Subgroup
analysis shows that the magnitude of these effects for
some of the outcomes varied between ICU patients and
elective surgery patients. In some cases, although the effect
is estimated as statistically significant for the whole consid-
ered population, this is not true for one or both sub-
groups, very probably as a consequence of the reduced
patient number in the analysed population. Some differ-
ences in laboratory parameters (bilirubin, triglycerides,
CRP, LTB4; data not shown) were not statistically signifi-
cant with the random effects model, but were statistically
significant when analysed with the less conservative, fixed
effects model. For five pre-specified outcomes, the inci-
dence of systemic inflammatory response syndrome
(SIRS), bleeding events, international normalized ratio
(INR), bleeding time, and creatinine clearance, data were
qualitatively or quantitatively insufficient to obtain a meta-
analytic effect estimate.
There are no clear data from RCTs on optimum doses,
while a case series analysis indicates that the optimal
dose may be related to the diagnosis [29]. Dosages used
are mainly related to body weight, and if anything can be
Table 3 n-3 PUFA-enriched versus standard parenteral lipid emulsions for parenteral nutrition: random effects meta-
analysis (Continued)
Non-ICU patients 4 373 -4.97 (-9.62, -0.32)*
Serum bilirubin, overall MD 4 520 0.03 (-0.33, 0.40)
ICU patients 3 321 0.12 (-0.42, 0.65)
Non-ICU patients 1 199 -0.02 (-0.17, 0.13)
Values in parentheses represent 95% CI. *Significant effect (P < 0.05). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein;
DHA,(%) docosahexaenoic acid content in serum/cellular membranes; EPA, (%) eicosapentaenoic acid content in serum/cellular membranes; (H) LOS, (Hospital)
length of stay; ICU, intensive care unit; LTB, leukotrienes B ; LTB ratio, LTB5: LTB4; MD, mean difference; RR, relative risk; SMD, standardised mean difference.
Figure 1 Infection rate: random effects meta-analysis and forest plot. Squares represent individual study mean of the effect measure,
diamonds represent its pooled estimates.
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observed from existing data, the dose at least, must
exceed 0.1 to 0.15 g/Kg/d fish oil. In order to address this
question, a clinical trial for optimal dose determination
has been designed and is being conducted (FOILED
study: ClinicalTrials.gov NCT01146821). Regarding the
optimal moment for starting parenteral lipids (pre- and/
or post-event), and possible effects on outcome, there are
no inferential data, although logical thinking may suggest
the earliest possible intervention.
The available pooled evidence in the present study on 3
PUFA-enriched parenteral regimens, in particular EPA
and DHA, in surgical and ICU patients presenting with
inflammatory conditions, indicates that their use is safe
and effective in reducing the morbidity burden and the
required hospitalization period. Moreover, results suggest
that the hypothesised mechanism by which these effects
are attained is plausible.
With n-3 PUFA-enrichment, the content in phospholi-
pids clearly shifts its balance towards the n-3 series, as
indicated by relevant and statistically significant increases
in EPA and DHA levels, without a significant decrease in
AA, which is reassuring in light of the important physio-
logical functions modulated by the latter. The more
favourable balance of n-3 versus n-6 PUFAs is reflected
in the increased release of less pro-inflammatory leuko-
trienes, such as LTB5, and particularly in the ratio
between these and more pro-inflammatory cell messen-
gers (LTB5/LTB4), and also by the reduction in cyto-
kines, such as IL-6, and of the inflammation marker CRP
(significantly reduced according to the fixed effects
model, but with a non-significant trend towards reduced
levels also in the more conservative random effects
model). Actually, regarding the velocity of IL-6 reduction
after peaking, there is more evidence in favor of n-3
Figure 2 Hospital length of stay: random effects meta-analysis and forest plot. Squares represent individual study mean of the effect
measure, diamonds represent its pooled estimates.
Figure 3 ICU length of stay: random effects meta-analysis and forest plot. Squares represent individual study mean of the effect measure,
diamonds represent its pooled estimates.
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PUFAs-enriched regimens than was possible to include in
the quantitative data pooling: Jiang et al. [21], Wachtler
et al. [15] and Weiss et al. [27] all report that IL-6 was
increased in controls, and reduced in patients receiving
n-3 PUFA-enriched regimens, and Wang et al. [16]
report a significant difference in favour of n-3 PUFA-
enriched regimens, but none of these reports included
adequate quantitative data.
Lung gas exchange assessed by the oxygenation index
is better-preserved or improved in patients receiving n-
3-enriched lipid emulsions than with standard lipid
emulsions. As for safety of use, no significant differences
among treatment groups could be detected in terms of
coagulation parameters, either for laboratory markers, or
the clinical outcome of blood transfusion requirements.
The same holds true for renal function: serum creati-
nine and urea were not significantly different among
treatment groups, and if anything can be deduced from
the data, this is a trend towards less impairment of kid-
ney function with n-3 PUFA-enriched emulsions. Liver
enzymes are significantly less increased in patients
receiving n-3 PUFA-enriched emulsions than in those
treated with standard lipid emulsions, suggesting a pos-
sible hepatoprotective action of fish oil components,
which should be studied further.
The clinical results obtained are consistent with
laboratory findings: although mortality is not signifi-
cantly affected, there is a clear advantage in terms of
infective complications and a relevant improvement in
recovery times, as indicated by the significant reduc-
tions in the ICU and hospital LOS. There is a not a
significant trend towards decreased mortality: possible
explanations of the failure to show a significant effect
include the low mortality risk in elective surgery
patients (< 5% in the considered control groups) and
the low overall patient numbers for high-mortality stu-
dies. However, the absence of a mortality difference
increases the value of the LOS reduction, as it cannot
be argued that this effect is a consequence of increased
mortality.
Figure 4 EPA concentration in plasma phospholipids: random effects meta-analysis and forest plot. EPA: eicosapentaenoic acid. Squares
represent individual study mean of the effect measure, diamonds represent its pooled estimates.
Figure 5 DHA concentration in plasma phospholipids: random effects meta-analysis and forest plot. DHA: docosahexaenoic acid. Squares
represent individual study mean of the effect measure, diamonds represent its pooled estimates.
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The fact that these results were obtained in studies in
which different formulations of n-3 PUFAs were com-
pared with a range of alternative lipid emulsions further
strengthens the concept of using lipid emulsions that
include the n-3 PUFA EPA and DHA. Our results confirm
and extend the scope of those obtained in the earlier ana-
lysis in surgical patients by Chen et al. [5]. We included a
greater number of studies and also evaluated data col-
lected from patients admitted to ICU. The only relevant
difference between outcomes considered in both analyses
is the reduced leukocyte LTB4 production, which reached
statistical significance with the fixed effects model.
Conclusions
In conclusion, these results confirm previous findings in
surgical patients and extend them to the ICU popula-
tion: the body of available evidence indicates that the
use of n-3 PUFA-enriched parenteral nutrition is safe
and effective in reducing the infection rate and hospital/
ICU stay in surgical patients, and that these benefits
also apply to ICU patients. Other beneficial effects
included reduced markers of inflammation, improved
lung gas exchange, liver function, antioxidant status and
fatty acid composition of plasma phospholipids, and a
trend towards less impairment of kidney function.
Key messages
• Enriching conventional lipid emulsions with n-3
PUFA results in a statistically and clinically signifi-
cant reduction in the infection rate and the length of
stay in the ICU, and in postsurgical patients receiv-
ing parenteral nutrition.
• Mortality is not decreased, possibly because of the
low mortality risk in the patient group as a whole.
• n-3 PUFA-enriched parenteral nutrition regimens
are well-tolerated and there is a trend towards less
impairment of kidney function, as well as significantly
improved liver function and lung gas exchange.
Additional material
Additional file 1: Figure S1. Prisma flowchart of study selection.
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